youtube_live
Q3 2026 earnings • in 3 days
See detailschevron_right
NTRA:NASDAQ
Natera Inc
$378.92
arrow_downward
-8.54%(-35.38) 1D
$377.22
arrow_downward
-0.45% (-1.70)bedtimeAfter hours
Closed: Nov 2, 4:00:00 PM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NTRA...
Open
$418.41
High
$418.41
Low
$376.38
Mkt. cap
54.62B
Avg. vol.
1.66M
Volume
2.63M
52-wk high
$437.41
52-wk low
$181.00
EPS
-$1.37
Beta
1.50
Shares outstanding
144.14M
No. of employees
6K
Open
$418.41
High
$418.41
Low
$376.38
Mkt. cap
54.62B
Avg. vol.
1.66M
Volume
2.63M
52-wk high
$437.41
52-wk low
$181.00
EPS
-$1.37
Beta
1.50
Shares outstanding
144.14M
No. of employees
6K
News stories
From web sources and news partners
GuruFocus
·
2 days ago
Natera (NTRA) CFO Michael Brophy Sells 3,084 Shares as Stock Tra
Investing.com
·
3 days ago
Natera CFO Michael Brophy sells $1.31 million in common stock
Profile
Natera, Inc. is a clinical genetic testing company based in Austin, Texas that specializes in non-invasive, cell-free DNA testing technology, with a focus on women's health, cancer, and organ health. Natera's proprietary technology combines novel molecular biology techniques with a suite of bioinformatics software that allows detection down to a single molecule in a tube of blood. Natera operates CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments in San Carlos, California and Austin, Texas. Wikipedia
About Natera Inc
CEOSteven Chapman
Employees6.14K
FoundedJan 1, 2004
HeadquartersAustin, Texas, United States
SectorBiotechnology
Websitenatera.com
Analyst ratings
Based on 21 analysts giving stock ratings to NTRA in the past 3 months
Strong buy
Buy
20
Hold
1
Sell
0
12-month forecast
Based on 21 Wall Street analysts offering 12 month price targets for NTRA in the last 3 months.
Highest
Current $378.92
$500.00 (+31.95%)
Average
$415.58 (+9.67%)
Lowest
$330.00 (-12.91%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Mark Massaro BTIG | Buy | Maintained | $430.00 | +13.5% | 10/27/2026 |
Max Masucci Roth MKM | Buy | Initiated | $475.00 | +25.4% | 10/22/2026 |
Kyle Mikson CFA Canaccord Genuity | Buy | Maintained | $500.00 | +32% | 10/19/2026 |
Eve Burstein Bernstein | Buy | Reiterated | $365.00 | -3.7% | 10/19/2026 |
Casey Woodring J.P. Morgan | Buy | Maintained | $460.00 | +21.4% | 10/14/2026 |
Daniel Brennan TD Cowen | Buy | Maintained | $480.00 | +26.7% | 10/13/2026 |
Kallum Titchmarsh Morgan Stanley | Buy | Reiterated | $435.00 | +14.8% | 10/13/2026 |
Luke Sergott Barclays | Buy | Maintained | $475.00 | +25.4% | 10/07/2026 |
Patrick B Donnelly Citi | Buy | Maintained | $480.00 | +26.7% | 10/06/2026 |
Albert Hu Citi | Buy | Maintained | $480.00 | +26.7% | 10/06/2026 |
Subbu Nambi Guggenheim | Buy | Maintained | $475.00 | +25.4% | 10/01/2026 |
Dan Leonard RBC Capital | Buy | Maintained | $460.00 | +21.4% | 09/24/2026 |
Evie Koslosky Goldman Sachs | Hold | Maintained | $375.00 | -1% | 09/20/2026 |
Unknown Analyst UBS | Buy | Maintained | $435.00 | +14.8% | 09/09/2026 |
Doug Schenkel UBS | Buy | Maintained | $435.00 | +14.8% | 09/09/2026 |
Jamie Clark Rothschild & Co Redburn | Buy | Initiated | $385.00 | +1.6% | 09/08/2026 |
David Westenberg Piper Sandler | Buy | Maintained | $363.50 | -4.1% | 08/24/2026 |
Tycho Peterson Jefferies | Buy | Maintained | $330.00 | -12.9% | 08/17/2026 |
Brendan Digan Citi | Buy | Maintained | $365.00 | -3.7% | 08/14/2026 |
Unknown Analyst Stephens | Buy | Maintained | $350.00 | -7.6% | 08/12/2026 |
Matt Larew William Blair | Buy | Reiterated | - | - | 08/07/2026 |
Daniel Markowitz CFA Evercore ISI | Buy | Maintained | $360.00 | -5% | 08/07/2026 |
Catherine Ramsey Schulte Robert W. Baird | Buy | Maintained | $348.00 | -8.2% | 08/07/2026 |
Brandon Couillard Wells Fargo | Hold | Maintained | $284.00 | -25.1% | 08/07/2026 |
Puneet Souda Leerink Partners | Buy | Maintained | $330.00 | -12.9% | 08/07/2026 |
William Bonello Craig-Hallum | Buy | Maintained | - | - | 07/09/2026 |
Paige Chamberlain Wolfe Research | Buy | Reiterated | $260.00 | -31.4% | 06/01/2026 |
Unknown Analyst Wolfe Research | Buy | Reiterated | $260.00 | -31.4% | 06/01/2026 |
Andrew Brackmann William Blair | Buy | Maintained | - | - | 05/08/2026 |
Unknown Analyst Jefferies | Buy | Reiterated | $275.00 | -27.4% | 02/27/2026 |
Next call in 3 days
Thu, Nov 5, 4:30 PM
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
- / -$0.28
Revenue / Est. (USD)
- / 707.50M
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 592.18M | 665.50M | 696.64M | 752.75M |
Cost of goods sold | 207.80M | 220.07M | 245.81M | 267.56M |
Cost of revenue | 207.80M | 220.07M | 245.81M | 267.56M |
Research and development expenses | 173.41M | 175.19M | 210.70M | 228.07M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 308.55M | 291.30M | 320.74M | 328.87M |
Operating expense | 481.96M | 468.21M | 537.15M | 562.65M |
Total operating expenses | 689.76M | 688.28M | 782.96M | 830.21M |
Operating income | -97.58M | -22.78M | -86.32M | -77.46M |
Other non operating income | - | - | - | - |
EBT including unusual items | -87.34M | -13.33M | -84.81M | -67.23M |
EBT excluding unusual items | -87.34M | -13.33M | -77.61M | -68.90M |
Income tax expense | 207.00K | -60.58M | 283.00K | -261.00K |
Effective tax rate | -0.24% | 454.63% | -0.33% | 0.39% |
Other operating expenses | - | - | - | - |
Net income | -87.54M | 47.26M | -85.09M | -66.97M |
Net profit margin | -14.78% | 7.10% | -12.21% | -8.90% |
Earnings per share | -0.64 | 0.36 | -0.60 | -0.47 |
Interest and investment income | 11.28M | 10.45M | 9.60M | 9.45M |
Interest expense | -1.04M | -991.00K | -892.00K | -890.00K |
Net interest expenses | 10.24M | 9.46M | 8.71M | 8.56M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | -87.28M | -13.69M | -66.09M | -56.27M |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events